1. Medtech Insight
  2. >>Policy & Regulation
  3. >>Legislation

Medtech Experts Endorse TCET In Health Subcommittee Hearing

 
• By Hannah Daniel

Leaders in the medtech industry testified before the House’s E&C Subcommittee on Health to advocate for coverage of innovative technologies.

People at table with microphones.
• Source: Shutterstock

The medtech industry showed its support of the Transitional Care for Emerging Technologies (TCET) proposal during a US House Energy and Commerce Subcommittee on Health Meeting on 18 July. The topic of the hearing was: “Innovation Saves Lives: Evaluating Medicare Coverage Pathways for Innovative Drugs, Medical Devices, and Technology.”

TCET, proposed by the Center for Medicare and Medicaid Services, would ensure transitional coverage of medical devices given the breakthrough designation by the US Food and Drug Administration until a...

More from Legislation

More from Policy & Regulation

Swiss Medtechs Advised To Work On US Tariff Mitigation Strategies

 
• By Ashley Yeo

The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.

FDLI: Clinical Labs Face Uncertainty After Texas Court’s LDT Ruling

 
• By Elizabeth Orr

A Texas court's decision against US FDA regulation of lab-developed tests (LDTs) has introduced new uncertainties for clinical labs. Industry stakeholders are now worried about potential future regulations while also managing existing compliance requirements. Recent conference discussions underscored the complexities of FDA oversight.

Inclusive By Design: UK Invites Sponsors To Submit Trial Diversity Plans

 
• By Vibha Sharma

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.